TFS
CRDF icon

TrustCore Financial Services’s Cardiff Oncology CRDF Stock Holding History

TrustCore Financial Services’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1 Hold
1
– – ﹤0.01% 1041
2022
Q3 		$0 Buy
+1
New +$2 ﹤0.01% 1072

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TrustCore Financial Services's CRDF Position: Q4 2022 in Review

TrustCore Financial Services held its Cardiff Oncology (CRDF) position steady in Q4 2022 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

TrustCore Financial Services first reported a position in CRDF in Q3 2022 and has held it in 2 quarters since. 58 funds tracked by Wall St. Rank hold CRDF as of Q4 2022.

  • TrustCore Financial Services held 1 share of Cardiff Oncology worth $1 as of Q4 2022.
  • TrustCore Financial Services left its Cardiff Oncology share count unchanged in Q4 2022.
  • Cardiff Oncology made up ﹤0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #1041 holding.
  • TrustCore Financial Services first reported a position in Cardiff Oncology in Q3 2022 and has held it in 2 quarters since.
  • 58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.